Stock Market

For the long term, I like the growth prospects of electric vehicle (EV) manufacturer Tesla (NASDAQ:TSLA). However, financial traders need to time their entry points carefully with TSLA stock. That’s a challenging task when Tesla’s chief executive is unpredictable. Some questions remain unanswered in 2023, it seems. Is Tesla’s strategy to lower its EV prices, or
0 Comments
Microsoft (NASDAQ:MSFT) is a member of the “Magnificent Seven” group of tech firms. However, don’t assume that MSFT stock will deliver magnificent returns like it did in 2023’s first half. Sure, Microsoft’s investors will get exposure to the artificial intelligence market. Yet, current and prospective shareholders should be aware of a significant competitor that Microsoft will
0 Comments
Plenty have thrown in the towel with positions in Lucid Group (NASDAQ:LCID), but many analysts and investors remain optimistic about the future prospects of LCID stock. While others have headed for the exits, they’ve held on, continuing to argue the consistently-questionable bull case for the struggling electric vehicle maker’s shares. In fact, just recently, the
0 Comments
Recent industry and macro factors caused Nvidia (NASDAQ:NVDA) stock to dip, sparking concerns about its 2023 rally. Despite a slight decline, don’t dismiss the ongoing generative AI mega trend driving its powerful performance.  That said, investors should recognize the limits of Nvidia’s growth potential despite the market’s enthusiasm for AI. While NVDA benefits from AI
0 Comments
In 2014, Massachusetts-based T2 Biosystems (NASDAQ:TTOO) went public at $11 per share. Expectations were high for the young startup. Its sepsis-detecting products targeted a $20.3 billion industry, and T2’s Magnetic Resonance Platform (T2MR) was potentially game-changing. Shares would quickly rise to a pre-split $23. The product, however, would prove a dud. In 2020, most of
0 Comments
Investors should expect a steep selloff among artificial intelligence stocks, as Wall Street cashes in on the high valuations many companies in this sector provide. On the other hand, some high-potential AI names remain overlooked, and the recent AI craze has done little to uplift their valuation. Thus, as the rally cools, smart investors will
0 Comments
The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups. These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see
0 Comments